Company type | Public |
---|---|
| |
Industry | Biopharmaceuticals |
Founded | 2018 |
Fate | Acquired by AbbVie (Pending) |
Headquarters | Cambridge, Massachusetts, U.S. |
Number of employees | 355 (March 31, 2024) |
Website | cerevel |
Cerevel Therapeutics Holdings, Inc. is a biotechnology and pharmaceuticals company focused on the development of novel therapies for mental and neurological illnesses.[1] Cerevel was established in October 2018, and is headquartered in Cambridge, Massachusetts.[2]
The company was formed in a collaboration between pharmaceuticals company Pfizer and private equity firm Bain Capital.[3][4]
In December 2023, AbbVie, an American pharmaceutical company, announced its intention to acquire Cerevel for US$8.7 billion.[5][6][7]
Cerevel uses novel approaches and technologies to develop its own drugs and treatment therapies. Its pipeline contains an array of drugs and therapies treating a range of conditions including Schizophrenia, Parkinson's, Epilepsy, mood disorders, and more.[8]
Notable Cerevel drugs and treatments at varying stages of development include:
Cerevel's tagline mission statement is to "unravel the mysteries of the brain" to treat neurological disease.[14] Scientifically, its approach to therapy development focuses on understanding the wiring of the brain, pursuing novel targets, and addressing specific receptor sub-types.[1]
The company has stated its approach to neurotherapy development can be viewed through three key lenses: